Clinical Trial Update: Personalized Targeted Inhibitors Treatment in Renal Cell Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating personalized targeted inhibitors for renal cell carcinoma was terminated; results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma Renal Cell
• Renal Cell Carcinoma

Snippet

Sponsor: The University of Texas Health Science Center, Houston | Conditions: Carcinoma, Renal Cell | Phase 2 | Status: TERMINATED | Results posted: 2018-10-12